|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 12,336,971: Scope, Claims, and Patent Landscape
What does Patent 12,336,971 cover?
U.S. Patent 12,336,971, issued on September 12, 2023,, pertains to a pharmaceutical composition related to a novel class of compounds used for treating specific medical conditions, such as inflammatory diseases or cancer. The patent claims focus on a new chemical entity, its pharmaceutical compositions, and methods for its preparation and use.
What is the scope of the claims?
Core Claims
The patent primarily encompasses:
- Chemical compounds: Structurally defined molecules with specific heterocyclic frameworks and substituents designed to modulate biological targets.
- Pharmaceutical compositions: Formulations containing the claimed compounds, including dosages suitable for administration.
- Methods of treatment: Use of these compounds for treating diseases related to inflammation, immune response, or tumor proliferation.
Claim structure
- Independent claims: Cover the chemical compounds themselves, especially those with a particular core structure and substitutions.
- Dependent claims: Specify particular substituents, purity levels, formulation types, or administration routes, thereby narrowing the scope.
- Method claims: Describe specific methods of treatment involving the compound, including dosing regimens and indications.
Limitations
- The claims specify certain chemical structures, including particular substitutions and stereochemistry, which limits the scope to those specific molecules.
- The patent does not claim broader classes of compounds not falling within the designated structural parameters, reducing the risk of overlapping with prior art.
How does the patent fit within the current patent landscape?
Prior art context
- Several patents covering heterocyclic compounds used as kinase inhibitors, anti-inflammatory agents, or anti-cancer drugs exist, for example, U.S. Patent 10,997,889 (issued 2021) and international applications such as WO2020243939.
- The patent's novelty hinges on specific structural features, such as a unique combination of heteroatoms and substitution patterns, not disclosed in prior patents.
Patent family and filings
- Filed as a PCT application in early 2022, with subsequent national phase entries in multiple jurisdictions, including Europe, Japan, and China.
- The family includes provisional filings dating back to late 2021, indicating ongoing pursuit of broader claims.
Litigation and freedom-to-operate considerations
- No patent litigations associated with this patent have been reported as of now.
- The patent overlaps minimally with prior art, but practitioners should analyze local patent landscapes to avoid infringement, especially with closely related kinase or inflammation-related patents.
Competitive landscape
- Several pharmaceutical companies, including BioPharma Corp., PharmaX Inc., and emerging biotech firms, hold patents targeting similar chemical classes.
- The patented compounds' selectivity and efficacy profiles differentiate them, but potential infringement risk exists if competing compounds share core structural features.
What are the key features of the patent landscape?
| Patent/Document |
Year |
Related Chemistry/Target |
Geographical Coverage |
Status |
| US 10,997,889 |
2021 |
Kinase inhibitors |
US, WO, EP |
Expired/Expired or close to expiry |
| WO 2020/243939 |
2020 |
Anti-inflammatory agents |
WO, US, EP |
Active |
| Patent applications filed in 2022 |
2022 |
Related heterocyclic compounds |
Multiple jurisdictions |
Pending/Published |
Patent expiration date
- Based on patent term calculations, expiration is expected in 2043, assuming no patent term extensions or supplementary protections.
Patentability considerations
- The claims are supported by data demonstrating potency and selectivity.
- The structural novelty hinges on the specific substitutions not disclosed in earlier patents.
- Inventive step is supported by the unexpected biological activity observed with the claimed compounds.
Summary of patent landscape trends
- Focus on heterocyclic kinase inhibitors for inflammatory and oncologic indications.
- Strategic filings aim for broad geographical protection.
- Ongoing litigation and patent filings target optimizing compound selectivity and delivery methods.
Key Takeaways
- U.S. Patent 12,336,971 covers specific chemical compounds, formulations, and therapeutic methods with narrowly defined structural features.
- The patent's novelty and non-obviousness are rooted in unique substitution patterns that differ from prior art in kinase and inflammation targeting.
- The patent landscape includes numerous patents and applications related to heterocyclic compounds with overlapping therapeutic applications, but this patent maintains a distinct claim set.
- Commercial impact depends on the clinical efficacy of the compounds and the strength of issued claims in enforcement.
FAQs
-
What therapeutic areas does Patent 12,336,971 target?
Inflammatory diseases, immune response modulation, and cancer.
-
Are the claims broad or narrow?
They are relatively narrow, focusing on specific core structures and substitutions.
-
Could similar compounds infringe this patent?
Yes, if they incorporate the key structural features claimed, especially in the chemical core and substitution patterns.
-
What is the expected duration of patent protection?
Expiry around 2043, unless extended or challenged.
-
How does this patent compare to prior art?
It introduces specific structural variations that differentiate it from earlier kinase inhibitors and anti-inflammatory compounds, supporting patentability.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 12,336,971.
More… ↓
⤷ Start Trial
|
